Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials
The aim of our study was to assess the efficacy and safety of sarpogrelate hydrochloride by comparing the effects of sarpogrelate with conventional treatment on the improvement of symptoms in PAD patients. The search was conducted in PubMed, Embase, Cochrane library database, CNKI, CBM for relevant...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2019-11, Vol.98 (46), p.e17266-e17266 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e17266 |
|---|---|
| container_issue | 46 |
| container_start_page | e17266 |
| container_title | Medicine (Baltimore) |
| container_volume | 98 |
| creator | Lu, Yunxin Li, Jiangmiao Xie, Jiayi Yu, Qingliang Liao, Liang |
| description | The aim of our study was to assess the efficacy and safety of sarpogrelate hydrochloride by comparing the effects of sarpogrelate with conventional treatment on the improvement of symptoms in PAD patients.
The search was conducted in PubMed, Embase, Cochrane library database, CNKI, CBM for relevant randomized controlled trials (RCTs) before January 1st, 2019. Inclusion and exclusion of studies, assessment of quality, outcome measures, data extraction and synthesis were completed by two reviewers independently. The meta-analysis was performed with RevMan 5.3.
Totally, 12 eligible RCTs were included in our analysis. Comparing the results of sarpogrelate group and control group, sarpogrelate significantly improved ankle-brachial index (ABI) levels (SMD = 0.05, [95%CI 0.20 to 0.74, P = .0005]), dorsalis pedis artery blood flow (MD = 0.16, [95%CI 0.09 to 0.23, P |
| doi_str_mv | 10.1097/MD.0000000000017266 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6867789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31725602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3554-907930f9a0a670c52dd4de2edb9c6cf0dd774af3aefed1bb9a347d78e16b76d43</originalsourceid><addsrcrecordid>eNpdkdtu1DAQhi0EokvhCZCQXyDFjk9rLpCqHgCpVW_KtTWJx03AG0d2lmp5-nq7UA6-mfH4_z-PZgh5y9kJZ9a8vz4_YX8ON63Wz8iKK6EbZbV8TlaMtaox1sgj8qqUb1UkTCtfkiNR1UqzdkW2FyFgvxSaAi2Q53SXMcKCdNj5nPohpjx6pGmiM-ZxHjBDpJCXeqmJHwtCwQ_0lG5wgQYmiLsyPtIyTD5txp_oaZ-mJacYa7rsfeU1eRFqwDe_4jH5enlxe_a5ubr59OXs9KrphVKyscxYwYIFBtqwXrXeS48t-s72ug_Me2MkBAEY0POusyCk8WaNXHdGeymOyccDd952G_Q91j4gujmPG8g7l2B0_75M4-Du0g-n19qYta0AcQD0OZWSMTx5OXP7Lbjrc_f_Fqrr3d_fPnl-j70K5EFwn2IdZfket_eY3YAQl-GRp4xtm5ZxyzlXrNmXpHgAVFSXCA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Lu, Yunxin ; Li, Jiangmiao ; Xie, Jiayi ; Yu, Qingliang ; Liao, Liang</creator><creatorcontrib>Lu, Yunxin ; Li, Jiangmiao ; Xie, Jiayi ; Yu, Qingliang ; Liao, Liang</creatorcontrib><description>The aim of our study was to assess the efficacy and safety of sarpogrelate hydrochloride by comparing the effects of sarpogrelate with conventional treatment on the improvement of symptoms in PAD patients.
The search was conducted in PubMed, Embase, Cochrane library database, CNKI, CBM for relevant randomized controlled trials (RCTs) before January 1st, 2019. Inclusion and exclusion of studies, assessment of quality, outcome measures, data extraction and synthesis were completed by two reviewers independently. The meta-analysis was performed with RevMan 5.3.
Totally, 12 eligible RCTs were included in our analysis. Comparing the results of sarpogrelate group and control group, sarpogrelate significantly improved ankle-brachial index (ABI) levels (SMD = 0.05, [95%CI 0.20 to 0.74, P = .0005]), dorsalis pedis artery blood flow (MD = 0.16, [95%CI 0.09 to 0.23, P < .001]) and pain-free walking distance (PFWD) (MD = 201.86, [95%CI 9.34 to 394.38, P = .04]). The pooled analysis showed that a significant decrease in hsCRP (MD = -0.57, [95%CI -1.12 to -0.02, P = .04]) and IL-6 (MD = 1.48,[95%CI 0.39 to 2.56, P = .008]) was observed in the sarpogrelate treatment.
Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000017266</identifier><identifier>PMID: 31725602</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Adult ; Aged ; Ankle Brachial Index ; Female ; Humans ; Male ; Middle Aged ; Peripheral Arterial Disease - drug therapy ; Peripheral Arterial Disease - physiopathology ; Platelet Aggregation Inhibitors - therapeutic use ; Randomized Controlled Trials as Topic ; Serotonin Antagonists - therapeutic use ; Succinates - therapeutic use ; Systematic Review and Meta-Analysis ; Treatment Outcome</subject><ispartof>Medicine (Baltimore), 2019-11, Vol.98 (46), p.e17266-e17266</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3554-907930f9a0a670c52dd4de2edb9c6cf0dd774af3aefed1bb9a347d78e16b76d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867789/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867789/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31725602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Yunxin</creatorcontrib><creatorcontrib>Li, Jiangmiao</creatorcontrib><creatorcontrib>Xie, Jiayi</creatorcontrib><creatorcontrib>Yu, Qingliang</creatorcontrib><creatorcontrib>Liao, Liang</creatorcontrib><title>Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>The aim of our study was to assess the efficacy and safety of sarpogrelate hydrochloride by comparing the effects of sarpogrelate with conventional treatment on the improvement of symptoms in PAD patients.
The search was conducted in PubMed, Embase, Cochrane library database, CNKI, CBM for relevant randomized controlled trials (RCTs) before January 1st, 2019. Inclusion and exclusion of studies, assessment of quality, outcome measures, data extraction and synthesis were completed by two reviewers independently. The meta-analysis was performed with RevMan 5.3.
Totally, 12 eligible RCTs were included in our analysis. Comparing the results of sarpogrelate group and control group, sarpogrelate significantly improved ankle-brachial index (ABI) levels (SMD = 0.05, [95%CI 0.20 to 0.74, P = .0005]), dorsalis pedis artery blood flow (MD = 0.16, [95%CI 0.09 to 0.23, P < .001]) and pain-free walking distance (PFWD) (MD = 201.86, [95%CI 9.34 to 394.38, P = .04]). The pooled analysis showed that a significant decrease in hsCRP (MD = -0.57, [95%CI -1.12 to -0.02, P = .04]) and IL-6 (MD = 1.48,[95%CI 0.39 to 2.56, P = .008]) was observed in the sarpogrelate treatment.
Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events.</description><subject>Adult</subject><subject>Aged</subject><subject>Ankle Brachial Index</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Peripheral Arterial Disease - drug therapy</subject><subject>Peripheral Arterial Disease - physiopathology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Serotonin Antagonists - therapeutic use</subject><subject>Succinates - therapeutic use</subject><subject>Systematic Review and Meta-Analysis</subject><subject>Treatment Outcome</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkdtu1DAQhi0EokvhCZCQXyDFjk9rLpCqHgCpVW_KtTWJx03AG0d2lmp5-nq7UA6-mfH4_z-PZgh5y9kJZ9a8vz4_YX8ON63Wz8iKK6EbZbV8TlaMtaox1sgj8qqUb1UkTCtfkiNR1UqzdkW2FyFgvxSaAi2Q53SXMcKCdNj5nPohpjx6pGmiM-ZxHjBDpJCXeqmJHwtCwQ_0lG5wgQYmiLsyPtIyTD5txp_oaZ-mJacYa7rsfeU1eRFqwDe_4jH5enlxe_a5ubr59OXs9KrphVKyscxYwYIFBtqwXrXeS48t-s72ug_Me2MkBAEY0POusyCk8WaNXHdGeymOyccDd952G_Q91j4gujmPG8g7l2B0_75M4-Du0g-n19qYta0AcQD0OZWSMTx5OXP7Lbjrc_f_Fqrr3d_fPnl-j70K5EFwn2IdZfket_eY3YAQl-GRp4xtm5ZxyzlXrNmXpHgAVFSXCA</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Lu, Yunxin</creator><creator>Li, Jiangmiao</creator><creator>Xie, Jiayi</creator><creator>Yu, Qingliang</creator><creator>Liao, Liang</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20191101</creationdate><title>Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials</title><author>Lu, Yunxin ; Li, Jiangmiao ; Xie, Jiayi ; Yu, Qingliang ; Liao, Liang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3554-907930f9a0a670c52dd4de2edb9c6cf0dd774af3aefed1bb9a347d78e16b76d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Ankle Brachial Index</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Peripheral Arterial Disease - drug therapy</topic><topic>Peripheral Arterial Disease - physiopathology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Serotonin Antagonists - therapeutic use</topic><topic>Succinates - therapeutic use</topic><topic>Systematic Review and Meta-Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Yunxin</creatorcontrib><creatorcontrib>Li, Jiangmiao</creatorcontrib><creatorcontrib>Xie, Jiayi</creatorcontrib><creatorcontrib>Yu, Qingliang</creatorcontrib><creatorcontrib>Liao, Liang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Yunxin</au><au>Li, Jiangmiao</au><au>Xie, Jiayi</au><au>Yu, Qingliang</au><au>Liao, Liang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>98</volume><issue>46</issue><spage>e17266</spage><epage>e17266</epage><pages>e17266-e17266</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>The aim of our study was to assess the efficacy and safety of sarpogrelate hydrochloride by comparing the effects of sarpogrelate with conventional treatment on the improvement of symptoms in PAD patients.
The search was conducted in PubMed, Embase, Cochrane library database, CNKI, CBM for relevant randomized controlled trials (RCTs) before January 1st, 2019. Inclusion and exclusion of studies, assessment of quality, outcome measures, data extraction and synthesis were completed by two reviewers independently. The meta-analysis was performed with RevMan 5.3.
Totally, 12 eligible RCTs were included in our analysis. Comparing the results of sarpogrelate group and control group, sarpogrelate significantly improved ankle-brachial index (ABI) levels (SMD = 0.05, [95%CI 0.20 to 0.74, P = .0005]), dorsalis pedis artery blood flow (MD = 0.16, [95%CI 0.09 to 0.23, P < .001]) and pain-free walking distance (PFWD) (MD = 201.86, [95%CI 9.34 to 394.38, P = .04]). The pooled analysis showed that a significant decrease in hsCRP (MD = -0.57, [95%CI -1.12 to -0.02, P = .04]) and IL-6 (MD = 1.48,[95%CI 0.39 to 2.56, P = .008]) was observed in the sarpogrelate treatment.
Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>31725602</pmid><doi>10.1097/MD.0000000000017266</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2019-11, Vol.98 (46), p.e17266-e17266 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6867789 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Aged Ankle Brachial Index Female Humans Male Middle Aged Peripheral Arterial Disease - drug therapy Peripheral Arterial Disease - physiopathology Platelet Aggregation Inhibitors - therapeutic use Randomized Controlled Trials as Topic Serotonin Antagonists - therapeutic use Succinates - therapeutic use Systematic Review and Meta-Analysis Treatment Outcome |
| title | Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A39%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20sarpogrelate%20hydrochloride%20on%20peripheral%20arterial%20disease:%20A%20meta-analysis%20of%20randomized%20controlled%20trials&rft.jtitle=Medicine%20(Baltimore)&rft.au=Lu,%20Yunxin&rft.date=2019-11-01&rft.volume=98&rft.issue=46&rft.spage=e17266&rft.epage=e17266&rft.pages=e17266-e17266&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000017266&rft_dat=%3Cpubmed_cross%3E31725602%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31725602&rfr_iscdi=true |